CareDx, Inc (NASDAQ:CDNA) Stock Position Raised by ARK Investment Management LLC

ARK Investment Management LLC lifted its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 7.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,194,722 shares of the company’s stock after buying an additional 515,399 shares during the period. ARK Investment Management LLC owned 13.30% of CareDx worth $86,337,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in CareDx by 127.6% during the 2nd quarter. Royal Bank of Canada now owns 8,430 shares of the company’s stock valued at $71,000 after purchasing an additional 4,726 shares during the period. WINTON GROUP Ltd acquired a new position in CareDx during the 3rd quarter valued at about $72,000. Tudor Investment Corp Et Al acquired a new position in CareDx during the 3rd quarter valued at about $81,000. Hsbc Holdings PLC acquired a new position in CareDx during the 3rd quarter valued at about $81,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in CareDx by 23.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,751 shares of the company’s stock valued at $82,000 after purchasing an additional 2,211 shares during the period.

CareDx Trading Up 9.9 %

Shares of NASDAQ:CDNA opened at $10.52 on Thursday. The company has a 50 day moving average of $9.66 and a 200-day moving average of $8.99. The firm has a market cap of $544.73 million, a P/E ratio of -2.97 and a beta of 1.42. CareDx, Inc has a twelve month low of $4.80 and a twelve month high of $12.93.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.97). The company had revenue of $65.57 million during the quarter, compared to analyst estimates of $63.66 million. CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The company’s revenue was down 20.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.34) earnings per share. Equities research analysts forecast that CareDx, Inc will post -1.59 EPS for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.